About Cidara Therapeutics, Inc. - Common Stock (CDTX)
Cidara Therapeutics is a biopharmaceutical company focused on the development of innovative therapies to treat infectious diseases and cancer. The company is particularly known for its work in advancing its Cloudbreak platform, which aims to enhance the effectiveness of existing antifungal drugs by improving their delivery and targeting mechanisms. Cidara emphasizes the importance of addressing the growing challenge of multidrug-resistant pathogens and is actively engaged in the research and development of new treatments to combat these threats and improve patient outcomes. Through its strategic approach, Cidara strives to meet critical medical needs and contribute to the advancement of healthcare solutions. Read More
Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement about their presentation at the upcoming ESWI 2025 conference. JP Morgan also began coverage of the stock, assigning it an Overweight rating and setting a price target of $200.
Cidara shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic influenza therapeutic and onshore its manufacturing.
With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?
Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said.
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.
